WO2019199986A1 - Dispositifs de soins de plaies, appareil et méthodes de traitement - Google Patents

Dispositifs de soins de plaies, appareil et méthodes de traitement Download PDF

Info

Publication number
WO2019199986A1
WO2019199986A1 PCT/US2019/026810 US2019026810W WO2019199986A1 WO 2019199986 A1 WO2019199986 A1 WO 2019199986A1 US 2019026810 W US2019026810 W US 2019026810W WO 2019199986 A1 WO2019199986 A1 WO 2019199986A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxygen
wound
therapy
dressing
pump
Prior art date
Application number
PCT/US2019/026810
Other languages
English (en)
Inventor
Srinivasan Sarangapani
Lawrence CALI
Original Assignee
Neogenix, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/950,290 external-priority patent/US10583042B2/en
Application filed by Neogenix, Llc filed Critical Neogenix, Llc
Publication of WO2019199986A1 publication Critical patent/WO2019199986A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/94—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with gas supply means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/60—Containers for suction drainage, adapted to be used with an external suction source
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/60—Containers for suction drainage, adapted to be used with an external suction source
    • A61M1/602—Mechanical means for preventing flexible containers from collapsing when vacuum is applied inside, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/98—Containers specifically adapted for negative pressure wound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/98—Containers specifically adapted for negative pressure wound therapy
    • A61M1/984—Containers specifically adapted for negative pressure wound therapy portable on the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0208—Oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/18—General characteristics of the apparatus with alarm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3331—Pressure; Flow
    • A61M2205/3334—Measuring or controlling the flow rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3331—Pressure; Flow
    • A61M2205/3344—Measuring or controlling pressure at the body treatment site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3368—Temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3546—Range
    • A61M2205/3569—Range sublocal, e.g. between console and disposable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3592—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8206—Internal energy supply devices battery-operated

Definitions

  • the present invention generally relates to wound care. More particularly, this invention relates to a mobile device and apparatus for the application of negative pressure wound therapy along with transdermal oxygen delivery.
  • Negative Pressure Wound Therapy may be used to treat wounds, including acute wounds, chronic wounds, pressure ulcers, and diabetic foot ulcers.
  • a dressing may be applied to a chronic wound to form an airtight seal, and a pump may be connected via a tube to the dressing to evacuate air from the dressing and draw drainage from the wound.
  • NPWT may accelerate wound healing by various mechanisms including: removal of exudate, reduction of edema, contraction of wound edges, stimulation of angiogenesis, changes in the wound edges, and production of granulation tissue.
  • wound treatment with NPWT may provide limited efficacy should the healing process stall or contraindications, such as advancing infection in the wound, develop.
  • oxygen delivery therapies may be used to successfully treat wounds, including wounds that have failed NPWT, a need exists for new devices and systems that may improve patient outcomes and expand access to patients with limited mobility or clinical support.
  • the present invention is directed to a wound care device and apparatus that may apply transdermal oxygen therapy and negative pressure wound therapy to a wound.
  • the wound care device and apparatus can be used to simultaneously apply transdermal continuous oxygen therapy and negative pressure wound therapy to a wound.
  • the wound care device and apparatus can be used for the intermittent application of one or both of negative pressure wound therapy and transdermal oxygen to a wound.
  • the wound care device and apparatus can be used for wound therapy carried out through alternating applications of negative pressure wound therapy and transdermal oxygen therapy.
  • the present invention is directed to a wound care device that includes a vacuum port for supplying a vacuum source to an external element, and an oxygen port for supplying oxygen gas to the same or another external element.
  • the device further may include an oxygen generating device fluidly connected to the oxygen port.
  • the oxygen concentrating device may include at least one membrane electrode assembly (MEA) for the production of oxygen from air.
  • the MEA may include a first electrode fluidly connected to ambient air, a second electrode spaced from the first electrode, the second electrode being fluidly connected to a first basin such that the first basin is fluidly connected to the oxygen port.
  • the MEA further may include a first ion conducting membrane positioned between the first and second electrodes, a first conductive wire connected to the first electrode, and a second conductive wire connected to the second electrode, such that the application of a constant electrical current through the first conductive wire to the second conductive wire electrochemically concentrates oxygen on the second electrode from ambient air adjacent the first electrode.
  • the device further may include a mechanical pump which comprises a pump intake fluidly connected to the vacuum port, and a motor for driving the mechanical pump such that the motor drives the mechanical pump to evacuate a gaseous mixture at an ambient temperature ranging from approximately 30°F to approximately l30°F and an ambient pressure ranging from approximately 600 mmHg absolute to approximately 760 mmHg absolute at a volumetric flow rate ranging from approximately 1 cc/min to approximately 2,500 cc/min while maintaining a vacuum at the pump intake.
  • the vacuum may range from approximately 1 mmHg to approximately 680 mmHg.
  • the device further may include a pressure sensor and a microcontroller.
  • the microcontroller may be electrically connected to the first MEA, the motor, and the pressure sensor.
  • the microcontroller may be configured to regulate operation of the wound care device in a plurality of operating modes. In a first operating mode, the first MEA delivers oxygen to the oxygen port at a rate ranging from approximately 1 ml oxygen/hr to approximately 10 ml oxygen/hr, at an ambient temperature of approximately 30°F to approximately l30°F and an ambient pressure of approximately 760 mmHg.
  • the mechanical pump evacuates a gaseous mixture from the vacuum port at a volumetric flow rate ranging from approximately 1 cc/min to approximately 2,500 cc/min while maintaining a vacuum ranging from approximately 560 mmHg to approximately 680 mmHg.
  • the electronic wound care device may be combined with a dressing to deliver transdermal continuous oxygen therapy, light suction, negative pressure wound therapy, and combinations thereof to a wound.
  • the dressing may be provided with one or more sensors to detect conditions at the wound bed, including a temperature sensor, an oxygen flow rate sensor, and an oxygen concentration sensor. Such sensors may detect conditions at the wound bed and may provide data indicative of such conditions to the microprocessor, in turn allowing the microprocessor to vary operation of the wound care device to optimize treatment for the current detected conditions at the wound bed.
  • the wound care device may be battery operated and portable.
  • FIG. 1 is a partially exploded schematic view of an exemplary wound care device in accordance with the present invention
  • FIG. 1A is a plan view of the interior side of the lid of the wound care device of FIG. 1;
  • FIG. 2 is a perspective view of another embodiment of a wound care device in accordance with the present invention.
  • FIG. 3 is a side view of the wound care device of FIG. 2;
  • FIG. 4 is a cross-sectional view of an embodiment of a dressing assembly in accordance with the present invention.
  • FIG. 5 is a schematic plan view of the dressing assembly of FIG. 4;
  • FIG. 5(a) is a schematic plan view of an alternative configuration of the dressing assembly of FIG. 4 including sensors for detecting conditions at the wound bed;
  • FIG. 6 is a cross-sectional view of another exemplary dressing assembly with a storage accessory for exudate in accordance with the present invention.
  • FIG. 7 is a schematic view of the dressing of FIG. 4 mounted on a leg wound of a human patient;
  • FIG. 8 is a schematic view of transdermal oxygen flow through the dressing and across the wound of FIG. 5;
  • FIG. 9 is a schematic view of another exemplary device for delivering NPWT and transdermal oxygen flow through a dressing and across a wound in accordance with the present invention.
  • FIG. 10 is a schematic view of yet another exemplary device for delivering NPWT and transdermal oxygen flow through a dressing and across a wound in accordance with the present invention
  • FIG. 11 is a perspective view of another embodiment of a wound care device in accordance with the present invention.
  • FIG. 12 is another perspective view of the wound care device of FIG. 11 with tubing for delivering NPWT, transdermal oxygen flow and other treatment therapies to a dressing and across a wound in accordance with the present invention
  • FIG. 13 shows an exploded view of the wound care device of FIG. 11;
  • FIG. 14 shows a perspective view of components of FIG. 13
  • FIG. 15 shows another perspective view of components of FIG. 13
  • FIG. 16 is a plan view of an illustrative printed circuit board (PCB) and rear enclosure section of the device of FIG. 14;
  • PCB printed circuit board
  • FIG. 17 is a plan view of the MEA assembly and front enclosure section of the wound care device of FIG. 14;
  • FIG. 18 is a perspective view of the wound care device of FIG. 11 with the front enclosure section removed;
  • FIG. 19 is a perspective view of the front enclosure section of FIG. 18 and an exploded view of the MEA assembly;
  • FIG. 20 is a cross-sectional view of the wound care device of FIG. 11, along line 20—20;
  • FIG. 21 is a block diagram of an exemplary wound care apparatus including the wound care device of FIG. 11, an exemplary dressing for applying wound care therapies to a wound, and an external container for trapping and storing wound exudates;
  • FIG. 21(a) is a schematic view of a voltage monitor for use with the wound care device of FIG. 11;
  • FIG. 22 is schematic overview of an exemplary embodiment of software architecture for electronically controlling operation of the wound care device of FIG. 11;
  • FIG. 23A is the first of two portions of an exemplary flow diagram of a first treatment mode of the wound care device of FIG. 11;
  • FIG. 23B is the second of two portions of the exemplary flow diagram of FIG 23 A;
  • FIG. 24A is the first of two portions of an exemplary flow diagram of a second treatment mode of the wound care device of FIG. 11;
  • FIG. 24B is the second of two portions of the exemplary flow diagram of FIG. 24A;
  • FIG. 25 is a schematic diagram of primary unit process operations for an exemplary therapy cycle in accordance with the first treatment mode of FIG. 23 A and FIG. 23B;
  • FIG. 26 is a schematic diagram of primary unit process operations for an exemplary therapy cycle in accordance with the second treatment mode of FIG. 24 A and FIG. 24B.
  • FIG. 1 shows an exploded view of an exemplary embodiment of a wound care device 50 in accordance with the present invention.
  • the wound care device 50 may include a lid (or upper housing component) 52, an oxygen concentrating device 54, a printed circuit board (PCB) 56, a battery pack 58, a vacuum pump 60, and a bottom enclosure (or lower housing component) 62.
  • a lid or upper housing component
  • PCB printed circuit board
  • the lid 52 may include an exterior surface 64 and an interior surface 66.
  • the interior surface 66 may include an oxygen collection chamber 68.
  • the lid 52 further may include a tubular port 70 on an exterior side wall portion of the lid.
  • the tubular port 70 may be in fluid communication with the oxygen collection chamber 68.
  • the perimeter of the oxygen collection chamber may be encircled by one or more adhesive strips 72.
  • the adhesive strip(s) 72 may provide an attachment structure for securing the oxygen concentrating device 54 to the lid.
  • the adhesive strip(s) 72 also may cooperate with the oxygen generating device to form a gas impermeable seal between the interior surface of the lid and the oxygen concentrating device such that the oxygen collection chamber is isolated from the housing interior.
  • the oxygen concentrating device may be associated with another part of the wound care device (e.g., an interior wall or compartment) provided that the relevant operational features of the oxygen concentrating device remain in fluid communication with an oxygen source (e.g., the ambient atmosphere).
  • an oxygen source e.g., the ambient atmosphere
  • the lid 52 may include openings or notches 74 to allow for entry of air into the housing interior.
  • the lid may include one or more projections 76 (e.g., locking tabs) which may extend from the interior surface 66. Each of the projections may mate with a corresponding receptacle 78 on the bottom enclosure 62 to connect the lid to the bottom enclosure.
  • the lid may be fixedly connected to the bottom enclosure to provide a tamper resistant seal.
  • the lid may be secured to the bottom enclosure by ultrasonic welding.
  • adhesive may be applied to the locking tabs so as to bond the lid to corresponding receptacles on the bottom enclosure.
  • the housing further may include a power switch 80.
  • the power switch may be a button switch, any suitable switching device may be used as long as the switching device provides reliable operation and is resistant to inadvertent operation.
  • the switching device may require the application of significantly greater force to deactivate (or power off) the device than to activate (or power on) the device.
  • two hands may be required to manipulate one or more safety locks in order to deactivate the device.
  • a tool may be required to deactivate the device.
  • the power switch may be centrally located on one side of the device, and the oxygen concentrating device 68 and oxygen port 70 may be located on an another side of the device.
  • the bottom enclosure 62 may include a power and/or air supply chamber 82 for supplying air and electricity to the oxygen concentrating device.
  • the base of the power and air supply chamber may be shaped to receive and hold a power supply for the device.
  • the middle and upper portion of the power and air supply chamber may be configured to securely accommodate a PCB upon which the control circuit for the device may reside.
  • the PCB includes pairs of terminals 84 which clip to individual batteries 86 and thus mechanically secure and electrically connect the power supply to the PCB and/or control circuit.
  • the bottom enclosure further may include a mechanical pump chamber 88.
  • the mechanical pump chamber 88 may be physically separated from the power and air supply chamber by a wall 90 so as to reduce the risk that operation of the mechanical pump may adversely impact oxygen concentration and delivery processes.
  • the mechanical pump chamber 88 may be configured and dimensioned to securely receive the vacuum pump (e.g., an electrically powered mechanical pump) 60 which may be used to evacuate gaseous substances and exudates from the wound environment.
  • the mechanical pump chamber may include an exterior wall.
  • the exterior wall may include another tubular port 92.
  • the other tubular port 92 may have a passageway 94 that extends from the tip of the tubular port to an interior surface of the mechanical pump chamber.
  • the bottom enclosure 62 may include openings (e.g., notches or pin holes) 96 in the exterior walls of the mechanical pump chamber in order to vent pump exhaust from the housing. Also, the bottom enclosure may include attachment sites (e.g., receptacles for locking tabs) 78 for connecting the lid to the bottom enclosure.
  • openings e.g., notches or pin holes
  • attachment sites e.g., receptacles for locking tabs
  • the housing may include openings 98 for a number of status indicators 100.
  • individual LEDs may be positioned in each opening to signal operational modes or alarms.
  • the oxygen concentrating device 54 may include a membrane electrode assembly (MEA) 102 for the electrochemical production of oxygen from air or water.
  • MEA membrane electrode assembly
  • an ion conducting membrane 104 may be positioned between two electrodes 106 which in turn are connected to a power source.
  • Oxygen in ambient air may be reduced to water at an interface region of the MEA between the cathode held at a reducing potential and the membrane.
  • the product water may be moved through the membrane to the anode held at an anodic potential, which oxidizes the water back to oxygen while releasing protons at an interface region between the anode and the membrane.
  • the protons may move through the membrane to the cathode to make possible continued reduction of oxygen from air.
  • the ion conducting membrane 104 may be any of a number of known ion conducting membranes which are capable of conducting protons and other ionic species.
  • Suitable membranes may include various perfluoronated ionomer membranes which include a poly(tetrafluoroethylene) backbone and regularly spaced perfluoronated polyether side chains terminating in strongly hydrophilic acid groups.
  • a preferred group of membranes suitable for use in the MEA include those containing sulfonic acid terminating groups on the side chains and available under the trademark Nafion® from E.I. Dupont Co. Nafion® is a perfluorinated polymer that contains small proportions of sulfonic or carboxylic ionic functional groups.
  • Other suitable membranes may include partially fluorinated membrane materials and those based on hydrocarbon polymer backbones.
  • the electrodes 106 used in the membrane electrode assembly may be in the form of a mesh or a thin coating on the opposite surfaces of the membrane.
  • the electrodes may be made of any materials which are electrically conductive and which will catalyze the reduction of gaseous oxygen into water, provide a voltage differential across the membrane to move the oxygen containing species, and catalyze the oxidation of the product water to release oxygen.
  • Suitable electrode materials include, but are not limited to, platinum, iridium, rhodium, and ruthenium, as well as their alloys and oxides in a pure finely divided form or as supported catalysts.
  • one method of making a membrane electrode assembly includes bonding a Pt/C electrode and a Pt black electrode 106 to either side of a Nafion® (or similar) membrane 104.
  • the electrical connections from the electrodes 106 to the voltage source (or power supply) may be provided through conducting end plates which may be made of graphite or metallic material.
  • a thin (e.g., 1-5 mil), electrically conducting and electrochemically inert wire is placed between the membrane and electrode during the bonding process, thereby making the electrical connection an integral part of the membrane electrode assembly.
  • wires include: gold, Pt, gold or Pt plated or deposited Ta, or tungsten, and other conducting materials such as carbon fiber.
  • a catalyst may be used to improve the electrochemical production of oxygen in the above reactions.
  • the addition of a catalyst in one or both electrodes aids in overcoming kinetic reaction barriers.
  • a Pt— Ru, Pt— Ir, or similar noble metal alloy catalyst that is poison resistant is used to coat the electrodes.
  • the use of such poison resistant catalysts will prevent impurities introduced from the adhesive and other components of the device from reducing the catalyst activity and deactivating the device.
  • Suitable non-limiting examples of anode catalysts include Pt— Ir, Pt— Sn, and ternary combinations thereof.
  • Suitable non-limiting examples of cathode catalysts include Pt— Ru/C, Pt— Sn, Pt— Ir, Pt— C, and ternary combinations thereof.
  • Each electrode further may be covered with a gas permeable/liquid impermeable barrier layer 110.
  • the gas permeable/liquid impermeable barrier layer may be heat bonded to the electrode.
  • These barrier layers may protect the polymer membrane, which otherwise might be damaged by contaminating foreign solids or liquids.
  • the gas permeable/liquid impermeable barrier layer may be formed from ePTFE (i.e., expanded polytetrafluoroethylene).
  • the MEA electrodes 106 may be connected to the control circuit via conductive wire(s) 108 embedded in each respective electrode.
  • the amount of oxygen generated by the MEA 102 may be varied by changing the current applied to the electrodes.
  • the device may produce between approximately 1 ml oxygen/hr and approximately 50 ml oxygen/hr, more preferably between approximately 3 ml/hr and approximately 10 ml/hr.
  • the mechanical pump 60 may be disposed in the mechanical pump chamber 88.
  • the mechanical pump may be a miniature diaphragm pump and may be driven by a DC motor. At standard conditions, the pump may operate over a pressure range of approximately 0 kPa to 165 kPa and a vacuum range of approximately 0 mmHg to 500 mmHg absolute.
  • the maximum unrestricted flow of the pump may be approximately 2.5 liters per minute (LPM). Operation of the mechanical pump may be controlled via pulse width modulation of the DC motor.
  • One commercially available pump which may be suitable for this application is a 2.5 LPM CTS Micro Diaphragm Pump manufactured by Parker Hannifin Corporation.
  • the pump intake may be connected to a manifold that includes a pressure sensor, a check valve, and a liquid isolation filter (e.g, a micron filter disc).
  • the manifold in turn, may be connected to the vacuum port 92, which may be connected via external tubing to a waste canister and wound dressing.
  • the pump discharge may be connected to a filter-muffler to assist with filtration and provide noise reduction.
  • the pump discharge may be released into the mechanical pump chamber 88.
  • the mechanical pump chamber further may include a number of notches or perforations 96 for releasing pump discharge exhaust to the housing exterior.
  • the PCB 56 may include control circuitry for operating the oxygen concentrating device, the mechanical pump, and the LED status indicators.
  • the control circuit also may include circuitry or devices for managing power from the power supply.
  • the control circuit may include a microprocessor and memory, a microcontroller, or an ASIC, along with other semiconductor devices and electronic components to provide the desired functionality.
  • the control circuit may include a microprocessor or programmable microcontroller to provide the device with enhanced functionality (e.g., user selection and adjustment of therapy settings), the control circuit may be implemented with basic controls and capabilities in order to provide a simple yet robust device that is suitable for use in acute care or home care settings.
  • the functionality of the device will include therapy monitoring based on measurements of MEA current usage as well as the pressure range of the mechanical pump vacuum intake.
  • the device control system may monitor the oxygen delivery rate and signal one or more status indicators should the MEA system cease to operate according to the prescribed therapy. Also, the device may monitor the pressure of the mechanical pump vacuum intake in order to determine whether there is a leak (i.e., the intake vacuum is less than the therapeutic range) or a blockage (i.e., the intake vacuum is greater than the therapeutic range) in the dressing or vacuum application line. Also, the device control system may signal one or more status indicators that the device and dressing apparatus are operating in accordance with the prescribed therapy.
  • the power supply 58 may include one or more electrical batteries 86.
  • the power supply may have a high energy density so as to provide maximum power for minimum volume and weight.
  • Non-limiting examples of battery types that may be suitable for the power supply include lithium-ion, alkaline and metal hydride batteries. Each battery may be manufactured according to a predetermined life span. For example, without limitation, the batteries may be designed to supply power continuously to the wound care device for at least 5, 7, or 10 days. Different sized batteries may be incorporated into a single oxygen producing device.
  • Other types of power sources include batteries, fuel cells, photovoltaic cells and supercapacitors in combination with one or more of the above power sources.
  • the control circuit, MEA, mechanical pump, and status indicators may be powered by one power supply, independent power supplies may be provided for one or more of these components.
  • the PCB may clip securely to the power supply.
  • the oxygen port 70 and the vacuum port 92 may conform to a standardized system of small-scale fluid fittings that are used for making leak-free connections between a male-taper fitting and its mating female part.
  • the oxygen port and the vacuum port may each include a Luer Lock fitting.
  • FIG. 4 shows an illustrative wound bed 114 prepared for NPWT and transdermal continuous oxygen therapy (TCOT) with an exemplary embodiment of a dressing 116 in accordance with the present invention.
  • the TCOT/NPWT dressing 116 may include a wicking layer which abuts and covers the wound bed 120.
  • the wicking layer 118 may be made from moisture-wicking synthetic fabric (e.g., Under Armour® or similar fabric).
  • the wicking layer 118 may draw exudates away from the wound and aid in establishing contiguous flow of oxygen across the wound bed 120.
  • the wicking layer may include an oxygen delivery manifold 122 to encourage topical delivery of oxygen to the wound.
  • the wicking layer may include a mixed gas and exudates removal manifold 124.
  • This manifold may facilitate distributed oxygen flow across the wound bed, and may promote waste gas and exudates removal from the wound.
  • the manifolds 122, 124 may be placed contra-laterally above the wound bed 120 to promote oxygen flow distribution and enhance contact time.
  • the oxygen delivery manifold 122 may be connected to a first length of flexible tubing 126.
  • the first length of flexible tubing 126 may include a standardized fluid fitting (e.g., Luer Lock fitting) 128 for connecting the other end of the flexible tubing to the oxygen port 70 of the wound care device 50.
  • the waste gas and exudates removal manifold 124 may be connected to a second length of flexible tubing 130.
  • the second length of flexible tubing 130 may include a standardized fluid fitting (e.g., Luer Lock fitting) 128 for connecting the other end of the second length of flexible tubing to an intermediate waste canister or directly to the vacuum port 92 of the wound care device.
  • the tubing may be made from a polymeric material suitable for use in hospital applications. Suitable materials for use in the tubing include, but are not limited to, silicone, polyethylene, polypropylene, polyurethane and various other thermoplastics.
  • the dressing 116 further may include an absorbent layer 132 above the manifold and wicking layer 118.
  • the absorbent layer 132 may hold exudates that are transported through the wi eking layer.
  • the absorbent layer 132 may provide structural support for the wound, the manifold and the first and second lengths of tubing. Additionally, the absorbent layer 132 may provide a protective barrier for the wound bed against physical trauma or microorganisms.
  • the absorbent layer may be gauze. In another embodiment, the absorbent layer may be polyurethane foam.
  • the dressing 116 further may include a semi-occlusive layer 134.
  • the semi-occlusive layer may be a sheet of transparent film.
  • the sheet of transparent film may include adhesive on one side to help create an air tight seal around the perimeter of the wound bed.
  • the semi- occlusive layer 134 may include penetrations for passage of the first and second lengths of tubing. The penetrations may be located above the dressing manifolds. Sealant may be applied around the penetration and the flexible tubing to form air tight seals.
  • the sheet of film may be a Tegaderm® dressing manufactured by 3M.
  • FIG. 5(a) shows a schematic plan view of an alternative configuration of dressing 116, including sensors to detect conditions at the wound bed.
  • Such sensors may detect conditions at the wound bed and may provide data indicative of such conditions to the microprocessor of the wound care device, in turn allowing the microprocessor to vary operation of the wound care device to optimize treatment for the current detected conditions at the wound bed.
  • an oxygen flow rate sensor 502 may be provided in dressing 116 to measure the flow rate of oxygen from the wound care device to dressing 116.
  • a temperature sensor 504 may be provided in dressing 116 to measure localized temperature at the wound bed.
  • an oxygen concentration sensor 506 may be provided in dressing 116 to measure the localized oxygen concentration at the wound bed.
  • Each of oxygen flow rate sensor 502, temperature sensor 504, and oxygen concentration sensor 506 is preferably in either wired or wireless data communication with the microprocessor of the wound care device.
  • data from oxygen flow rate sensor 502 may be used by the microprocessor to regulate the flow of oxygen from the wound care device through oxygen delivery manifold 122 so as to maintain the oxygen flow rate at the wound bed at a desired level appropriate for the individual treatment.
  • data from temperature sensor 504 may be used by the microprocessor to report localized temperature of the wound bed, in turn allowing notification of abnormal temperature so that medical personnel can take appropriate action.
  • data from oxygen concentration sensor 506 can be used by the microprocessor to regulate the flow of oxygen from the wound care device through oxygen delivery manifold 122 so as to maintain the oxygen volume at a desired level for the individual treatment.
  • the foregoing oxygen flow rate sensor 502, temperature sensor 504, and oxygen concentration sensor 506 are of standard configuration well known to those of ordinary skill in the art and are readily commercially available, and thus are not further detailed in this specification.
  • a bacterial sensor (such as that disclosed in U.S. Patent Application Publication No. US 2017/0247739 Al, the specification of which is incorporated herein by reference in its entirety) comprising an electrochemical microfluidic device may be provided and embedded in dressing 116 for detecting, for instance, pyocyanin, indicating the presence of bacterial infection.
  • pyocyanin indicating the presence of bacterial infection.
  • Such detection of the presence of bacterial infection may likewise trigger an audible or visual alarm (such as illumination of an LED), in turn indicating that treatment from the wound care device described herein should be continued.
  • FIG. 6 shows an illustrative wound bed prepared for NPWT and TCOT therapy with another exemplary embodiment of a dressing 136 in accordance with the present invention.
  • This embodiment is similar to the dressing of FIG. 4 as described above.
  • This embodiment includes an integral bag 138 for storing waste exudates.
  • the integral bag 138 may be flexible and possess a low profile to facilitate patient comfort and mobility.
  • the integral bag 138 may include internal spacers 140 which may prevent flexible portions of the bag from collapsing and occluding exudates and waste gas flow under negative pressure.
  • FIG. 7 shows a schematic representation of the dressing of FIG. 6 applied to a leg wound of a patient.
  • the dressing 136 may be oriented such that the oxygen delivery manifold 122 is closer to the patient’s knee 142 and the mixed gas and exudates removal manifold (or vacuum application manifold) 124 is closer to the patient’s ankle 144.
  • the dressing 136 and flexible tubing 126, 128 may be secured with a strap 146 at the top end and the bottom end of the dressing assembly to allow the patient to ambulate. Additional straps may be used to secure the vacuum supply tubing and the oxygen delivery tubing along the length of the patient’s leg.
  • the straps may have fastening elements for providing an adjustable fit.
  • the fastening elements may be hook and loop fasteners (e.g., Velcro® strips).
  • FIG. 8 shows a schematic representation of mass flow 148 across an exemplary wound 120 being treated with NPWT and transdermal oxygen therapy.
  • oxygen at a maximum rate of approximately 3 cc/hr to approximately 4 cc/hr may be continuously directed to the wound bed by the oxygen delivery manifold.
  • the vacuum application manifold may apply negative pressure to the wound bed to create a maximum return-gas flow rate of approximately 1 cc/hr. It is believed that the balance of oxygen delivered to the wound bed may be naturally absorbed or consumed by tissue in or around the wound.
  • the head space of the wound inside the dressing assembly may stabilize at an oxygen concentration in the range of approximately 20 percent to 75 percent.
  • the head space of the wound inside the dressing assembly may stabilize at an oxygen concentration of approximately 70 percent.
  • the non-oxygen head space gases in the dressing may include tissue off gases (e.g., carbon dioxide) from natural processes such as respiration from the wound.
  • Oxygen delivery pressure may adjust to whatever pressure may be needed to accommodate the generation rate of oxygen determined by the current flow.
  • Oxygen delivery pressure to the dressing may be slightly greater than the pressure in the headspace of the wound environment in order for the oxygen to flow to the wound.
  • the oxygen delivery pressure may reach an average pressure of approximately 680 mmHg absolute because the pressure in the headspace of the wound environment may range from approximately 660 mmHg to 680 mmHg.
  • the vacuum level at the wound may be adjusted by the control system to achieve the desired therapeutic conditions.
  • the MEA may operate under a constant current mode to enable oxygen generation. For example, the MEA may generate oxygen at a rate of 3cc/hr.
  • the controller may vary the level of the current in order to adjust the rate of oxygen production
  • the MEA may be operated at a constant current so the flow of oxygen to the wound may be maintained by the backpressure of oxygen in the MEA assembly, the vacuum applied to the wound space by the mechanical pump, and respiration of the wound.
  • the control system may vary the vacuum level by activating the mechanical pump.
  • the mechanical pump speed further may be controlled through pulse width modulation.
  • the mechanical pump speed may be set to zero and the polarity of the MEA reversed. Tinder these conditions, the MEA may operate under constant voltage to generate a vacuum at the oxygen delivery manifold.
  • the vacuum generated by the MEA may range from approximately 1 mmHg to approximately 50 mmHg.
  • the reduction in negative pressure applied by the MEA in this mode of therapy may benefit healing processes in the wound by temporarily reducing wound tissue strain.
  • a wound healing device for the application of oxygen and the removal of wound exudates is discussed in Ti.S. Patent No. 8,088,113, which is incorporated herein by reference in its entirety.
  • FIG. 9 shows a schematic diagram of another embodiment of a wound care device 152 connected to a dressing 116 for applying transdermal oxygen therapy and negative pressure wound therapy to a wound 150.
  • the apparatus may include an MEA 102, a vacuum pump 60, and a housing 154 for these components.
  • the housing may include a gas/liquid barrier 156 between the MEA 102 and the mechanical pump 60.
  • the gas/liquid barrier 156 may divide the housing 154 into two chambers.
  • the first chamber 158 of the device may include the MEA (or cell) and oxygen port.
  • the MEA may interact with air outside the housing to produce nearly pure oxygen in the first chamber.
  • the second chamber 160 of the device may include the intake of the vacuum pump and the vacuum port 92.
  • the mechanical pump intake may include a fitting that includes a pressure sensor and a liquid impermeable filter.
  • the second chamber may include a liquid trap 162 for storing or containing exudates that have been evacuated from the wound 150 and drawn into the housing 154 under negative pressure.
  • a check valve 164 connecting the two chambers 158, 160 may allow gas flow from the second chamber 160 to the first chamber 158.
  • the check valve 164 may be a flap valve.
  • the oxygen port 70 may be connected via flexible tubing 128 to a dressing 116 for delivering oxygen to the wound 150.
  • the vacuum port 92 may be connected via flexible tubing 130 to the dressing to apply negative pressure to the wound 150.
  • the liquid trap 162 may operate based on mechanical principles or chemical-mechanical principles.
  • the liquid trap 162 may be designed to operate independently of the device’s orientation.
  • the treatment device of FIG. 9 may be designed with the exudates trap on the outside of the housing. An external exudates trap may be removable from the housing.
  • FIG. 10 shows a schematic diagram of another device 166 that may be used with a dressing 116 to simultaneously apply transdermal oxygen therapy and negative pressure wound therapy to a wound.
  • the device may include two MEAs 168, 170, a mechanical pump 172, and a housing 154.
  • the device 166 may include a first MEA 168 that concentrates oxygen in a first internal compartment 174 of the housing.
  • the first internal compartment 174 may be connected to an oxygen port 70 for delivery to the wound.
  • the vacuum pump intake 92 may be connected a second internal compartment 176 in the housing.
  • the second internal compartment 176 may be connected to a vacuum port 92 for applying negative pressure to the wound.
  • the second MEA 170 may be configured to consume oxygen from the exudates reservoir 162 and contribute to, or when operating alone create, a negative pressure in the second internal compartment 176.
  • a passage 178 may connect the second internal compartment 176 to the third internal compartment 180 adjacent the second MEA 170.
  • one MEA 168 may be dedicated to generating oxygen for the oxygen port 70 and another MEA 170 may be dedicated to generating negative pressure in the second compartment 176 and vacuum port 92.
  • the second internal compartment 176 further may include a drain 182 for removing exudate evacuated from the wound via negative pressure.
  • the second internal compartment 176 may be configured to store exudates independent of the housing orientation.
  • the device may be connected to a dressing via flexible tubing.
  • FIG. 11 shows another embodiment of a wound care device 184 in accordance with the present invention.
  • the wound care device 184 may include an exterior housing 186.
  • the housing may include two or more sections. The sections may be connected to form an enclosure for holding and containing internal components of the wound care device.
  • the housing may include two sections l86a, l86b which may be secured together to form a tamper resistant, water resistant enclosure.
  • the enclosure may house process equipment, electronic controls, communication devices, and power supply equipment that enable a mobile and self-contained wound care device which is capable of providing a portable oxygen supply and a portable vacuum supply for administering transdermal oxygen therapy, NPWT, light wound suction, and other prescribed wound care therapies involving combinations thereof.
  • the housing (or enclosure) 186 may include an oxygen supply port 70, a vacuum supply port 92, a vacuum pump exhaust port 188, and a power switch 190.
  • One or more of the ports may include a Luer lock fitting.
  • the enclosure includes three status indicator windows l92a, l92b, l92c.
  • One status indicator window l92a may include a light pipe for an LED that signals a low battery condition (i.e., a battery low indicator).
  • a second status indicator window l92b may include another light pipe for another LED that signals whether there is a leak or blockage in the dressing or vacuum application line (i.e., pressure excursion indicator).
  • the third status indicator window l92c may include yet another light pipe for yet another LED that signals whether the device is on and/or operating in accordance with the prescribed wound care therapy.
  • the enclosure 186 may be designed to possess a low profile configuration that prevents entanglement with other bodies or external objects.
  • the enclosure may have a length (L) and a width (W) of approximately equal dimension, and a height (H) that is less than the other two dimensions.
  • the housing may have a length of approximately 2.75 inches, a width of approximately 2.625 inches, and a height of approximately 1.43 inches.
  • the external features of the housing may be smooth and rounded.
  • the wound care device may be connected to a retaining clip (or holster) 194 which may be secured to a belt or strap 196 for mounting on (or near) a patient.
  • the housing and retaining clip may form a press-fit connection.
  • the enclosure 186 may be considered to have a front side 198, a rear side 200, a right side 202, a left side 204, a top side 206, and a bottom side 208.
  • the rear side 200 of the enclosure may face the retaining ring clip 194.
  • the front side 198 of the enclosure may face away from the retaining clip.
  • the top side 206 of the enclosure may include the power switch, and the bottom side 208 of the enclosure may include the oxygen supply port 70 and the vacuum supply port 92.
  • the left side 204 of the enclosure may include the vacuum pump exhaust 188.
  • the enclosure 186 may be formed from plastic, a reinforced polymer material, metal alloy or other strong durable material suitable for use in a medical device.
  • the enclosure may be formed from ABS (acrylonitrile butadiene-styrene) plastic.
  • the wound care device may include a front enclosure section l86a, a printed circuit board 210, a fixed power supply 212, a rear enclosure section l86b that includes a replaceable power supply compartment 214, a replaceable power supply 216 and a cover 218 for the replaceable power supply compartment.
  • the wound care device 184 further may include a retaining clip 194.
  • the front enclosure section l86a may include an oxygen supply port 70, an MEA assembly chamber 220, three light pipes 222, a vacuum pump chamber 224, and four locking tabs 226 for securing the front enclosure section to the rear enclosure section.
  • a wall 228 may separate the MEA assembly chamber 220 from the vacuum pump assembly chamber 224.
  • the front enclosure section further may include a cutout 230a in the left side wall and another cutout 230b in the bottom side wall.
  • the PCB 210 may include a power switch 232 and a mechanical slide 234 for activating the power switch, process control circuitry 236 including a microcontroller 238, a contact spring assembly 240 for electrically connecting the control circuitry to the MEA assembly, a vacuum pump and motor assembly 242, a vacuum pump intake 244 and associated tubing 246, a vacuum pump discharge 248 and associated fittings and tubing 250, a pressure sensor assembly 252 and associated tubing 254, and dedicated MEA power supply terminals 256 (see FIG. 15). As shown in FIG. 15, the MEA power supply terminals 256 may be configured and dimensioned for a standard or custom battery type.
  • the PCB 210 further may include a dedicated power supply circuit and a power supply (i.e., coin battery) for regulating operation of the wound care device.
  • the rear enclosure section l86b may include an MEA power supply storage compartment 258, a vacuum pump exhaust port 188 and connector fitting 260, a vacuum supply port 92 and connector fitting 262, as well as power supply cradles 264, and receptacles for receiving the front enclosure section locking tabs 266.
  • the rear enclosure section l86b further may include a storage compartment 214 (and cover), as well as terminals 268 for a dedicated vacuum pump power supply.
  • the vacuum pump power supply terminals 268 may be configured and dimensioned for a standard or custom battery type.
  • the rear enclosure section l86b further may include a smooth, flat recessed surface 270 for receiving one or more product labels.
  • FIG. 16 shows a plan view of the PCB 210 mounted in the rear enclosure section l86b.
  • the vacuum pump 242 is in fluid communication with the vacuum supply port 92.
  • the vacuum pump intake port 244 is connected via tubing 246 to one branch of a T-fitting 272 that is connected to the vacuum supply port 92.
  • the other branch of the T-fitting 272 is connected to a pressure sensor assembly 252 by a conduit 254.
  • the conduit 254 may be flexible tubing.
  • the vacuum pump discharge port 248 is in fluid communication with the vacuum pump exhaust port 188.
  • the vacuum pump discharge port 248 is connected to a fitting that via tubing 250 is connected to another fitting that is connected to the vacuum pump exhaust port 188.
  • status indicator LEDs 274 may be positioned on the PCB. Each LED 274 may interact with a dedicated light pipe 222 to visually signal the status of selected operational processes.
  • the PCB 210 further may include, without limitation, a set of contacts 276 for programming the microcontroller, as well as one or more power circuits. Additionally, the PCB 210 may include memory, a data bus, and/or
  • the MEA assembly 278 may be attached to the interior surface of the front enclosure section l86a.
  • the interior surface of the front enclosure section may include a basin (or sink/recess) 280a.
  • Basin 280a may be positioned under MEA 282a.
  • Basin 280a may further include a sidewall 284a.
  • An intermediate passage 286 extends from sidewall 284a of basin 280a to a distribution passage 288, which in turn connects to the oxygen supply port 70.
  • the intermediate passage 286 and the distribution passage 288 are aligned to facilitate fluid communication between sink 280a and the oxygen supply port 70.
  • the MEA assembly 278 may include an inert gasket 290 disposed between MEA 282a and the front enclosure section l86a.
  • the gasket 290 may have a hole 292a that conforms to the shape and location of the sink 280a, as well other holes 294 that are compatible with the MEA assembly.
  • the MEA 282a then may be clamped to the front enclosure section with a frame (or plate) 295.
  • the frame 295 also may conform to the shape and location of the sink 280a and may include holes 296 that present a pattern that conforms to the other holes 294.
  • the MEA electrodes may be connected via conductive wires 298a, 298b to a PCB landing pad 300. As shown in FIGS. 17 and 18, the PCB landing pad 300 may be secured with screws 302 to a dedicated seat 304 located adjacent to the MEA 282a.
  • the electrical contacts 298a, 298b on the landing pad 300 are situated above the spring loaded contact assembly 240.
  • the electrical contacts 298a, 298b on the landing pad 300 are pressed against the respective contacts on the spring loaded contact assembly 240 to electrically connect the MEA 282a to electrical circuitry on the PCB 210.
  • the wound care device 184 may include an oxygen supply MEA 282a, a vacuum pump and motor 242a, 242b, a pressure sensor 252, a power supply and electronic controls, LEDs 222, and input/output devices 276.
  • a dressing 116 may be connected to the wound care device 184 to provide treatment for a wound 114.
  • a canister (or exudate trap) may be positioned between the dressing and the vacuum supply port of the vacuum pump to collect and store exudates from the wound. The canister may be combined with the dressing 136 as shown in FIG. 6.
  • a pressure sensor 252 may be positioned at the vacuum supply port. The pressure sensor 252 may be part of the control circuitry that regulates the operation of the wound care device.
  • the pressure sensor 252 may be used by a control circuit to monitor the pressure applied to the dressing and to adjust (or control) operation of the vacuum pump 242a to maintain a desired therapeutic vacuum level inside the dressing (e.g., 80-100 mmHg). Operation of the vacuum pump 242a may be regulated by the control circuit, as well as by duty cycle requirements as determined by any local process controls.
  • the oxygen supply MEA 282a may be operated by a circuit that provides a constant current across the membrane electrodes.
  • the power supply may include independent sources and circuits for the vacuum pump motor 242b and the MEA 282a.
  • the power supply for the control circuit that may regulate operation of the wound care device as a whole may be independent, as well.
  • the power supply for the control circuit may be derived from one of the other two power supplies.
  • the status indicator LEDs 222 and any other input/output devices may be connected to the control circuit as well.
  • the control circuit will include a microcontroller 238 that has been pre-loaded with firmware to regulate operation of the wound care device.
  • the device 184 may be loaded with a standard firmware program for one of a number of wound care therapies.
  • the firmware may be updateable. Accordingly, a patient specific modality of treatment may be prescribed by a doctor and loaded into the device.
  • a constant current circuit configured for use in a system as set forth herein includes a transistor responsible for maintaining a l3mA drive current through the MEA, and has a minimum collector-emitter voltage.
  • a voltage monitor 400 (shown generally at 400) may be provided to measure the voltage between MEA 282a and the drive transistor 410, and produce a warning signal to alert the user if the voltage at this node is insufficient to maintain constant current through MEA 282a. As shown in FIG.
  • voltage monitor 400 may be implemented, by way of non-limiting example, using the analog comparator peripheral of the readily commercially available Microchip PIC12F635 microcontroller 412 (commercially available from Microchip Technology Inc.) and a 200m V reference voltage derived from the divided output of a commercially available LT6650 400mV reference IC (commercially available from Linear Technology Corporation).
  • the 200mV reference is provided to the positive comparator input 414, and the negative comparator input 416 is connected to the node between MEA 282a and drive transistor 410.
  • a signal at the comparator output within microcontroller 412 is driven to a logic high (the 200mV reference was particularly selected in order to allow for a maximum of l.2Volts across MEA 282a with L91 battery cells 414 nearly at full discharge state of l.4Volts).
  • Firmware running on the microcontroller 412 monitors that comparator output signal within the main software loop. If the comparator output is low, the circuit is working properly and a short-duration LED flash is used as an indicator of normal function. Likewise, if the comparator output is high, the firmware of microcontroller 412 initiates a long duration LED flash indicating to the user that the device may not be producing the specified gas output.
  • the user i.e., patient
  • the exemplary software architecture overview 308 for regulating operation of the wound care device 184 may include the following configuration.
  • the wound care device 184 may be turned on by closing a mechanical switch.
  • the wound care device may then power on 310 and activate a state machine.
  • the state machine may be a microcontroller.
  • the state machine may connect with the following components: a timer 312, a manufacturer system check 314, a pressure monitor 316, an MEA control 318, a vacuum pump control/monitor 320, a battery monitor 322, and LED states 324.
  • a timer 312 a manufacturer system check 314, a pressure monitor 316, an MEA control 318, a vacuum pump control/monitor 320, a battery monitor 322, and LED states 324.
  • a timer may be initiated at startup and may be updated during each cycle of the state machine. If the wound care device has been operating for seven days, the microcontroller may disable the device. The timer may track“on” time in blocks of time. For example, without limitation, each block of time may be 10 minutes.
  • a manufacturer system check may be initiated at startup and may be updated during each cycle of the state machine.
  • the manufacturer system check would verify operation of system components (e.g., the MEAs and vacuum pump) and then light the appropriate LED based on the status of the check.
  • a pressure monitor check may be initiated at startup and may be updated during each cycle of the state machine.
  • the pressure sensor may be positioned near the vacuum pump intake or the MEA oxygen supply outlet. If the wound care device is operating properly, the measured value at these two locations should be related and close in value.
  • the pressure monitor check may monitor the pressure near the vacuum pump intake and the MEA oxygen supply outlet.
  • MEA control may regulate operation of the MEA.
  • the MEA may be off (or non- operational), in an oxygen generation mode in which the MEA operates on constant current, or in an oxygen consuming mode in which the MEA operates on constant voltage.
  • Pump control may regulate operation of the vacuum pump via the motor.
  • the pump may be off (or non-operational), or on but subject to duty cycle limitations.
  • the pump may be controlled using a pulse width modulation voltage supply.
  • the pump operation may be regulated to provide a target pressure of between 80-100 mmHg vacuum at the vacuum pump inlet.
  • the battery voltage of each power supply may be monitored. If the voltage of the replaceable batteries falls below a certain level, an LED warning light may be lit.
  • LEDs may be lit to reflect the operating status of the wound care device.
  • FIG. 23A and FIG. 23B show a schematic flow chart 326 for an exemplary TCOT and NPWT treatment mode that may be used to regulate operation of the wound care device.
  • the treatment mode may start when the wound care device is powered on 328.
  • the system timer may be updated 330, and the value of the system timer may be compared to a pre-set value 332 that determines the duration of the treatment cycle.
  • the exemplary duration of the treatment cycle is seven days. If the value of the system timer is seven days or more, then an LED warning 334 is given to provide a visual signal that the treatment cycle has been completed.
  • the wound care device then may be disabled 336.
  • the replaceable power supply is evaluated 338 to determine whether the batteries should be replaced. For example, the voltage of the replaceable power supply may be measured and if the measured value of the replaceable power supply voltage is less than a pre-set value, then an LED warning 340 is given to provide a visual signal that the batteries in the replaceable power supply compartment should be replaced. The visual signal may be cleared 342 by replacing the batteries in the replaceable power supply. After the LED warning 340 has been cleared 342 or if the batteries did not need to be replaced, then a system check 344 may be undertaken.
  • system check 344 determines that the system is not OK (e.g., has not passed the required system checks)
  • an LED warning 334 is given to provide a visual signal that the system is not OK.
  • the wound care device then may be disabled 336. If, however, the system check 344 determines that the system is OK (e.g., has passed the required system checks), then wound treatment processes may be monitored and regulated.
  • the monitoring and regulation of wound treatment processes may start with an evaluation of the pressure 346 of the dressing headspace, which may be measured in the vacuum line, at the wound site, or in the oxygen delivery line. If the measured pressure is higher than the desired range, then the vacuum pump is turned on. For example, the pressure measurement may be collected from a pressure sensor in the vacuum line at (or near) the vacuum pump intake. If the pressure measurement indicates that the vacuum level in the dressing is not low, then no action is taken with the pump. After assessing and/or regulating the operation of the vacuum pump, the treatment program may assess and/or regulate operation of the MEA.
  • An oxygen generation timer may be pre-set to a value TOG that determines the duration of oxygen generation in a dual action treatment sub-cycle.
  • the oxygen generation timer may be evaluated to determine whether the oxygen generation timer is done 350. If the oxygen generation timer has not expired, then the MEA may be operated in a constant current setting 352 to concentrate oxygen for delivery to the dressing.
  • the system timer may be updated 330 and the subroutine continued. After the oxygen generation timer expires, the oxygen generation timer and the oxygen consumption timer may be reset 358. Then the system timer 330 may be updated, and the subroutine continued.
  • FIG. 25 depicts the operating state of the vacuum pump and oxygen generating MEA for an exemplary TCOT and NPWT dual action 60 minute sub-cycle in accordance with the schematic flow chart of FIG. 23 A and FIG. 23B, where the oxygen generation timer value is set to a value of, by way of non-limiting example, 60 minutes (and thus operates in a continuous oxygen generation mode).
  • the exemplary TCOT and NPWT dual action sub-cycle of FIG. 25 would be completed every hour for the duration of the treatment cycle, which in this example is seven days.
  • the top waveform corresponding to operation of the vacuum pump power shows maintenance of a desired vacuum (as factory set or selected by the clinician) based on the input from the pressure sensor.
  • the vacuum pump will be switched “ON” and “OFF”, depending upon the reading of the pressure sensor. More particularly, when the pressure sensor reading is above a set value, the pump will be turned on. Likewise, when the sensor reading indicates a pressure lower than the set value, the pump will be turned off. At the same time, the MEA will be continuously generating oxygen, thus maintaining an oxygen rich environment in the wound bed, albeit at a negative pressure range set by the clinician / operator. In this mode both negative pressure therapy and continuous oxygen therapy are applied simultaneously.
  • FIG. 24A and FIG. 24B show a schematic flow chart for an exemplary TCOT and intermittent NPWT treatment mode that may be used to regulate operation of the wound care device.
  • the treatment mode may start when the wound care device is powered on 362.
  • the system timer may be updated 364, and the value of the system timer may be compared 366 to a pre-set value that determines the duration of the treatment cycle.
  • the duration of the treatment cycle is seven days. If the value of the system timer is seven days or more, then an LED warning 368 is given to provide a visual signal that the treatment cycle has been completed.
  • the wound care device 184 may then be disabled.
  • the replaceable power supply is evaluated 370 to determine whether the batteries should be replaced. For example, the voltage of the replaceable power supply may be measured and if the measured value of the replaceable power supply voltage is less than a pre-set value, then an LED warning 368 is given to provide a visual signal that the batteries in the replaceable power supply compartment should be replaced. The visual signal may be cleared 372 by replacing the batteries in the replaceable power supply. After the LED warning 368 has been cleared, or if the batteries did not need to be replaced, a system check may be undertaken 374.
  • system check 374 determines that the system is not OK (e.g., has not passed the required system checks)
  • an LED warning 376 is given to provide a visual signal that the system is not OK.
  • the wound care device 184 may then be disabled 378. If, however, the system check 374 determines that the system is OK (e.g., has passed the required system checks), then wound treatment processes may be monitored and regulated.
  • a vacuum interval timer may be pre-set to a designated value that determines the interval between the start of the MEA assembly dual action sub-cycle (DASC) and the start of NPWT. Additionally, a vacuum mode timer may be pre-set to a designated value that determines the duration of NPWT in this exemplary prescribed therapeutic sub-cycle (PTSC).
  • DASC MEA assembly dual action sub-cycle
  • PTSC therapeutic sub-cycle
  • the vacuum interval timer may be evaluated to determine whether the vacuum interval timer has expired 380. If the vacuum interval timer has not expired and the oxygen generation timer has not expired 382, then the MEA may be operated in a constant current setting 384 to concentrate oxygen for delivery to the dressing. The system timer may be updated 364 and the subroutine continued. After the oxygen generation has expired, the oxygen generation timer may be reset 390. Then the system timer may be updated 364, and the subroutine continued.
  • the monitoring and regulation of wound treatment processes may start with an evaluation of the pressure of the dressing headspace, which may be measured in the vacuum line, at the wound site, or oxygen delivery line. If the measured pressure is higher than the desired range, the vacuum pump is turned on 392. For example, the pressure measurement may be collected from a pressure sensor in the vacuum line at (or near) the vacuum pump intake. If the pressure measurement indicates that the vacuum level in the dressing is not low, then no action is taken with the pump. The monitoring and regulation of the vacuum pump operation may continue until the vacuum mode timer expires 394. After the vacuum mode timer expires 394 the oxygen timers are reset 390, as the oxygen generation timer 382 has expired. Then the system timer 364 may be updated, and the subroutine continued.
  • FIG. 26 depicts the operating state of the vacuum pump and the oxygen generating MEA for an exemplary TCOT and intermittent NPWT sub-cycle in accordance with the schematic flow chart of FIG. 24 A and FIG. 24B.
  • the time durations of the two therapies may be chosen by the clinician based upon the specific clinical characteristics of the wound to be treated. Initially, oxygen generating function will be turned on for a pre-set time interval as set by the clinician. In the exemplary therapeutic treatment shown in FIG. 26, the oxygen generation timer value is set to a value of 45 minutes. At the end of the oxygen application time interval, the power to the MEA is turned off, and the vacuum pump is activated to provide NPWT. In the exemplary therapeutic treatment shown in FIG.
  • the vacuum interval timer is set to a value of 45 minutes, and the vacuum mode timer is set to 15 minutes.
  • the prescribed therapy sub-cycle would be completed every hour for the duration of the treatment cycle, which in this example is seven days.
  • the particular duration of oxygen therapy and negative pressure therapy are either predetermined at factory set levels or are chosen by the clinician based upon an assessment of the wound under treatment. This operating mode allows continuous application of at either one of the two treatments continuously for a predetermined period of time and at alternating intervals.
  • the foregoing devices and dressings may be combined to form an apparatus that may be used to provide negative pressure wound therapy and transdermal oxygen therapy to a wound.
  • the apparatus may include a treatment device which houses an MEA oxygen concentrator and the mechanical pump for delivering negative pressure, as well as a dressing that includes inlet and outlet connections terminating in a manifold to facilitate a substantially uniform flow of oxygen across the treatment area.
  • the treatment devices may be disposable and may be designed for a single clinical use. For example, the treatment device may be designed to operate continuously for at least 7 days. In another example, the treatment device may be designed to operate continuously for at least 15 days. In another example, the treatment device may be designed to operate continuously for at least 30 days. And, in yet another example, the treatment device may be designed to operate continuously for at least 60 days.
  • the dressings and tubing may be adapted for use specifically with the treatment device(s). As these consumables may be replaced on an as needed basis, the dressing(s) and tubing may be available in individually sealed sterile packaging.
  • treatment of a wound involving negative pressure wound therapy and transdermal oxygen therapy may be ordered by a physician.
  • the dressing may be placed in the wound and the surrounding area may be covered with the semi-occlusive layer.
  • Two openings may be created in the semi-occlusive layer above the dressing’s vacuum and oxygen supply manifolds, respectively.
  • the tubing associated with each manifold then may be passed through the respective openings.
  • the dressing and semi-occlusive layer may be provided in an integral configuration. Sealant may be used to provide an airtight seal around the tube penetrations in the semi-occlusive layer.
  • the oxygen supply tubing may be connected to the oxygen port of the device.
  • the vacuum supply tubing may be connected to the vacuum port of the device.
  • the treatment device may be powered on by depressing (or otherwise activating) the power button.
  • the device may undergo a start up process that includes a diagnostic assessment which confirms that the device is operating properly, that the apparatus does not include a leak or blockage, and that the differential pressure between the oxygen supply and vacuum supply is in the expected range of a fresh dressing.
  • the results of the diagnostic assessment may be reported to the status indicators and any correction of any identified adverse conditions may be required before a treatment operation may commence.
  • the MEA may be operational (“on”) or nonoperational (“off’).
  • the MEA When the MEA is on and in a first operational mode, the MEA may be concentrating atmospheric oxygen for delivery to the oxygen supply port at a rate ranging from approximately 1 cc/hour to approximately 100 cc/hour. The concentrated oxygen, which may be nearly pure, may be delivered to the dressing and wound environment.
  • the MEA when the MEA is on and in a second operational mode, the MEA may be consuming oxygen from the dressing headspace at a very rapid rate (e.g. a rate ranging from about 5 to about 50 times greater than the respective oxygen generation rate of the MEA under normal operating conditions).
  • the oxygen consumption rate of the MEA may be related to the current delivering capability of the power supply and the amount of oxygen available for consumption. In view of the above, consumption of oxygen by the MEA may result in the application of a vacuum to the dressing and wound site.
  • the vacuum applied by the MEA to the wound site may range from approximately 1 mmHg to approximately 50 mmHg.
  • the mechanical pump may be operational (“on”) or nonoperational (“off’).
  • the mechanical pump may evacuate waste gas and liquid exudate at a rate in the range of approximately 1 cc/min to approximately 2,500 cc/min.
  • the vacuum applied to the dressing manifold may range from approximately 560 mmHg to approximately 680 mmHg.
  • the treatment devices may initiate a first treatment modality in which the MEA is in the first operational mode and the mechanical pump is in the third operational mode.
  • the MEA may supply oxygen to the dressing at a rate of approximately 3 cc/min and the mechanical pump may be operationally controlled to apply a vacuum of approximately 100 mmHg to the dressing and a maximum throughput (or flow rate) of approximately 1 cc/hour.
  • the balance of the supplied oxygen i.e., 2 cc/hour
  • the supply of oxygen is controlled by the amount of current passing between the MEA electrodes.
  • the applied vacuum may be set by the pump speed which may be controlled through pulse width modulation.
  • the pump speed may operate at a set point and the pump operation may be regulated with a microprocessor controlled power switch capable of regulating the“on” and“off’ timing intervals according to the programmed values.
  • the first treatment modality may apply NPWT and transdermal oxygen therapy to the wound.
  • Treatment administered using the devices of FIG. 1 or FIG. 9 may initiate a second treatment modality with the MEA in the second operational mode and the mechanical pump on standby.
  • the polarity of the MEA may be switched, and a constant voltage may be applied across the MEA electrodes.
  • treatment administered by the device of FIG. 10 and FIG. 11 may include an MEA dedicated to supplying negative pressure to the wound, as set forth in copending and co-owned U.S. Patent Application No. 15/715,319.
  • the second treatment modality may apply lower levels of suction to the wound than applied during NPWT.
  • the treatment devices may initiate a third treatment modality with an oxygen concentrating MEA in the first operational mode and the mechanical pump on standby. Accordingly, the third treatment modality may apply transdermal oxygen therapy to the wound.
  • the treatment devices may initiate a fourth treatment modality with an oxygen concentrating MEA in standby and the mechanical pump in the third operational mode. Accordingly, the fourth treatment modality may apply NPWT to the wound.
  • the foregoing treatment modalities may be combined into sequences of treatment (or therapies).
  • the sequence of treatment modalities applied by the devices to a wound may be programmed into the functionality of the device and manually set or implemented by a user of the device. Accordingly, the device may allow for the application of a wide combination of therapies for treating wounds in a mobile device that may be adapted to the therapeutic and clinical needs of the patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

L'invention concerne un dispositif de soins de plaies pour administrer une oxygénothérapie topique et une thérapie de plaie par pression négative pour le traitement d'une plaie. Le dispositif de soins de plaies peut comprendre un dispositif d'électrode à membrane d'alimentation en oxygène (MEA), une pompe à vide et un moteur, un capteur de pression et une alimentation électrique et des commandes électroniques. Un pansement peut être relié au dispositif de soins de plaies pour administrer une oxygénothérapie topique continue et une thérapie de plaie par pression négative à une plaie. Le dispositif de soin de plaie peut être utilisé pour fournir une oxygénothérapie topique et une thérapie de plaie par pression négative simultanées, une oxygénothérapie continue avec une thérapie de plaie par pression négative intermittente, et une oxygénothérapie et une thérapie de plaie par pression négative en alternance.
PCT/US2019/026810 2018-04-11 2019-04-10 Dispositifs de soins de plaies, appareil et méthodes de traitement WO2019199986A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/950,290 2018-04-11
US15/950,290 US10583042B2 (en) 2014-08-08 2018-04-11 Wound care devices, apparatus, and treatment methods

Publications (1)

Publication Number Publication Date
WO2019199986A1 true WO2019199986A1 (fr) 2019-10-17

Family

ID=68164578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/026810 WO2019199986A1 (fr) 2018-04-11 2019-04-10 Dispositifs de soins de plaies, appareil et méthodes de traitement

Country Status (1)

Country Link
WO (1) WO2019199986A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788682A (en) * 1995-04-28 1998-08-04 Maget; Henri J.R. Apparatus and method for controlling oxygen concentration in the vicinity of a wound
US20060287632A1 (en) * 2001-12-12 2006-12-21 Srinivasan Sarangapani Oxygen producing device for woundcare
US20090149821A1 (en) * 2005-05-10 2009-06-11 Scherson Daniel A Novel portable electrochemical devices for dual action wound healing
US20100217177A1 (en) * 2009-02-24 2010-08-26 Cali Lawrence J Oxygen-Producing Bandage With Releasable Oxygen Source
US20110130712A1 (en) * 2008-05-21 2011-06-02 Moris Topaz Wound healing device
US20120016322A1 (en) * 2010-07-19 2012-01-19 Kci Licensing, Inc. Systems and methods for electrically detecting the presence of exudate in dressings

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788682A (en) * 1995-04-28 1998-08-04 Maget; Henri J.R. Apparatus and method for controlling oxygen concentration in the vicinity of a wound
US20060287632A1 (en) * 2001-12-12 2006-12-21 Srinivasan Sarangapani Oxygen producing device for woundcare
US20090149821A1 (en) * 2005-05-10 2009-06-11 Scherson Daniel A Novel portable electrochemical devices for dual action wound healing
US20110130712A1 (en) * 2008-05-21 2011-06-02 Moris Topaz Wound healing device
US20100217177A1 (en) * 2009-02-24 2010-08-26 Cali Lawrence J Oxygen-Producing Bandage With Releasable Oxygen Source
US20120016322A1 (en) * 2010-07-19 2012-01-19 Kci Licensing, Inc. Systems and methods for electrically detecting the presence of exudate in dressings

Similar Documents

Publication Publication Date Title
US11844672B2 (en) Wound care devices, apparatus, and treatment methods
US10583042B2 (en) Wound care devices, apparatus, and treatment methods
US10245392B2 (en) Oxygen concentrating device, wound care apparatus, and treatment methods
US11511055B2 (en) Oxygen concentrating device, wound care apparatus, and treatment methods
JP5819391B2 (ja) 流体収集キャニスタ内で使用するための電気接点保護を伴うセンサおよびそれを含む陰圧創傷療法システム
US11529503B2 (en) Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
US10632018B2 (en) Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
EP0942768B1 (fr) Appareil de regulation de la concentration d'oxygene a proximite d'une blessure
WO2017205556A1 (fr) Joint à pression négative pour un pansement pour thérapie gazeuse
AU2016366165B2 (en) Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability
WO2019199986A1 (fr) Dispositifs de soins de plaies, appareil et méthodes de traitement
WO2022040614A1 (fr) Système portable et procédé de modification de l'environnement de fluide d'une oreille
AU2015201152B2 (en) Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19785083

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 25/03/2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19785083

Country of ref document: EP

Kind code of ref document: A1